Joulia J M, Pinguet F, Ychou M, Duffour J, Topart D, Grosse P Y, Astre C, Bressolle F
Laboratoire d'Onco-Pharmacologie, Centre Regional de Lutte contre le cancer, Montpellier, France.
Anticancer Res. 1997 Jul-Aug;17(4A):2727-30.
The pharmacokinetics of 5-fluorouracil (5-FUra) were investigated in 16 patients with metastatic colorectal cancer receiving high-dose folinic acid (LV 200 mg/m2) followed by 5-FUra bolus (400 mg/m2) and continuous infusion (600 mg/m2) on days 1 and 2. Quantitation of unchanged drug was assessed by a highly specific high-performance liquid chromatographic method. The concentrations of 5-FUra at the end of the loading dose averaged 30.7 +/- 13.2 micrograms/ml (i.e., 236 microM). The steady-state plasma concentration averaged 0.31 +/- 0.11 microgram/ml (i.e., 2.4 microM). 5-FUra plasma levels declined rapidly after the end of infusion with an apparent elimination half-life of 7.08 +/- 3.21 minutes. Clearance ranged from 776 to 3023 ml/min/m2. Large patient-to-patient variations in plasma 5-FUra concentrations were observed. No toxicity greater than WHO grade 2 was seen. One patient experienced grade 1 stomatitis and two others experienced grade 1 and 2 myelosuppression. One patient developed diarrhoea and another suffered asthenia. Nausea and vomiting were observed in 5 patients.
对16例转移性结直肠癌患者的5-氟尿嘧啶(5-FUra)药代动力学进行了研究,这些患者在第1天和第2天接受大剂量亚叶酸(LV 200 mg/m²),随后推注5-FUra(400 mg/m²)并持续输注(600 mg/m²)。采用高特异性高效液相色谱法对未变化的药物进行定量。负荷剂量结束时5-FUra的浓度平均为30.7±13.2微克/毫升(即236微摩尔)。稳态血浆浓度平均为0.31±0.11微克/毫升(即2.4微摩尔)。输注结束后5-FUra血浆水平迅速下降,表观消除半衰期为7.08±3.21分钟。清除率范围为776至3023毫升/分钟/平方米。观察到患者之间血浆5-FUra浓度存在较大差异。未观察到大于世界卫生组织2级的毒性。1例患者出现1级口腔炎,另外2例患者出现1级和2级骨髓抑制。1例患者出现腹泻,另1例患者出现乏力。5例患者出现恶心和呕吐。